Guggenheim upgraded shares of Enliven Therapeutics (NASDAQ:ELVN – Free Report) to a strong-buy rating in a report released on Monday,Zacks.com reports.
A number of other brokerages have also recently commented on ELVN. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. HC Wainwright upped their price target on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Mizuho upped their price target on shares of Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research report on Wednesday, March 25th. The Goldman Sachs Group upped their price target on shares of Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $53.17.
View Our Latest Analysis on ELVN
Enliven Therapeutics Stock Up 6.8%
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. Research analysts expect that Enliven Therapeutics will post -1.7 earnings per share for the current fiscal year.
Insider Activity at Enliven Therapeutics
In other news, Director Richard A. Heyman sold 1,230 shares of Enliven Therapeutics stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total transaction of $32,201.40. Following the completion of the sale, the director directly owned 22,647 shares of the company’s stock, valued at approximately $592,898.46. The trade was a 5.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Benjamin Hohl sold 10,000 shares of Enliven Therapeutics stock in a transaction on Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at $1,508,580. This represents a 16.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 25.90% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Enliven Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of ELVN. KBC Group NV purchased a new position in shares of Enliven Therapeutics during the first quarter valued at about $38,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Enliven Therapeutics by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after buying an additional 594 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after buying an additional 930 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Enliven Therapeutics during the fourth quarter valued at approximately $83,000. Finally, Quantbot Technologies LP grew its holdings in shares of Enliven Therapeutics by 47.1% during the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after buying an additional 1,434 shares during the last quarter. 95.08% of the stock is owned by institutional investors.
Enliven Therapeutics Company Profile
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Articles
- Five stocks we like better than Enliven Therapeutics
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
